Clinical Edge Journal Scan

Atorvastatin plus nortriptyline: A promising combination for migraine therapy


 

Key clinical point: Compared with nortriptyline alone, its combination with atorvastatin significantly reduces the frequency of headache and improves the quality of life (QOL) in patients with migraine; however, the effect on migraine intensity is nonsignificant.

Major finding: A torvastatin plus nortriptyline vs. nortriptyline alone led to a significantly lower headache frequency ( P = .004) at week 24 in addition to a significant improvement in the QOL at weeks 14 and 24 (both P = .001); however, no significant difference was observed in the headache intensity over 24 weeks.

Study details: This prospective, triple-blind, randomized controlled trial included 68 adult patients with migraine who were randomly assigned to receive atorvastatin plus nortriptyline (n = 34) or placebo plus nortriptyline (n = 34) for 24 weeks.

Disclosures: The study was supported by a grant from the Research and Technology Department of Shahid Sadoughi University of Medical Sciences, Yazd, Iran. The authors reported having no conflicts of interest.

Source: Sherafat M et al. Neurol Res. 2022 (Jan 17). Doi: 10.1080/01616412.2021

Recommended Reading

How is migraine associated with cardiovascular and cerebrovascular events?
Migraine ICYMI
Therapeutic alpha-lipoic acid supplementation may improve migraine symptoms
Migraine ICYMI
Prophylactic treatment lifts the quality of life in pediatric migraine
Migraine ICYMI
Postoperative migraine: General and neuraxial anesthesia may be equally potent risk factors
Migraine ICYMI
Clinical Edge Journal Scan Commentary: Migraine February 2022
Migraine ICYMI
Clinical Edge Journal Scan Commentary: Migraine February 2022
Migraine ICYMI
PACAP38- and VIP-induced cluster headache attacks do not appear to alter CGRP levels
Migraine ICYMI
Headache and Covid-19: What clinicians should know
Migraine ICYMI
Galcanezumab improves functioning and reduces disability in treatment-resistant migraine
Migraine ICYMI
Rimegepant lowers MMDs and tablet use and improves HRQoL in migraine
Migraine ICYMI